Home Business Wire Botanical Solution, Inc. Secures Additional $7 Million, Totaling Over $13 Million in...

Botanical Solution, Inc. Secures Additional $7 Million, Totaling Over $13 Million in Series A Funding

Investment will be used to scale up the GMP production of the vaccine adjuvant, QS-21, and fulfill the supply agreements with Croda and other Big Pharma companies

DAVIS, Calif.–(BUSINESS WIRE)–Botanical Solution Inc. (BSI), the multiple award-winning innovator of sustainable, highly consistent and cost effective Advanced Botanical Materials, has successfully secured an additional $7 million investment.

Following the announcement of a partnership with Croda to accelerate the production of a green, high quality and pharma spec QS-21 at kilogram scale under GMP standards, the Company has gone further in demonstrating, through internal programs and collaboration with big pharma companies, that its product is biochemically comparable and as immunogenic as the traditional QS-21, obtained from very old soapbark trees that grow predominantly in Chile.

The new investment enables BSI to develop a robust and truly sustainable supply chain for the gold standard vaccine adjuvant QS-21, and boosts the expansion plan for agriculture, which includes the roll out of BSI’s flagship product Quillibrium® in Mexico, Brazil, the US and EU. The successful partnership with Syngenta established since 2019 has produced over 50% YOY growth of effective growers’ adoption of the product in Chile and Peru, accumulating over 100,000 acres treated to date.

The financing round, led by Otter Capital, was joined by the Latin American investors Boldo SpA and Quebec LP controlled by the Casanueva and Saval family offices focused on high tech and pharma investments respectively, among other investors.

BSI is on track to start delivering GMP materials to be used in the development of human vaccines later in the year.

According to CEO Gaston Salinas, “BSI is fortunate to have a strong group of investors who are enthusiastic about our progress and vision to impact multiple industries through our breakthrough technology and truly sustainable products. BSI is in a privileged position to solve major issues affecting the supply chain, cost and sustainability of the vaccine adjuvant QS-21 and addressing major challenges associated with disease control in modern agriculture.”

About BSI

Botanical Solution Inc., a Delaware Corporation, has a proprietary platform for sustainable and improved production of consistent, high quality Advanced Botanical Materials (ABM). ABM-01 is the first ABM produced by the company, based on a plant called Quillaja saponaria. ABM-01 is the active ingredient used in two gold standard products, BSI’s biopesticide Quillibrium® and the vaccine adjuvant QS-21, used in a Shingles blockbuster vaccine, a recently launched RSV vaccine and a Malaria vaccine. The Company has received a widespread industry recognition for innovation, winning the “2023 Best Process Innovation Award” from ICIS Chemical Business, the 2022 “New Biotech Business of the Year Award” from BioProtection Forum and the “2022 Product of the Year Award” from S&P Crop Science.

To learn more visit us at www.botanical-solution.com/news


Media Contact:


Se questo articolo ti è piaciuto e vuoi rimanere sempre informato sulle novità tecnologiche